Management of the kidney transplant recipient.
The short-term outcomes of kidney transplant recipients have improved dramatically in the past 20 years, in large part resulting from the availability of more potent immunosuppressive drugs capable of preventing or treating acute allograft rejection. Ironically, side effects from these same immunosuppressants play a role in the long-term morbidity and mortality of this patient population. As kidney transplant recipients survive for longer periods of time with functioning allografts, primary care physicians will likely become more involved in their management, mandating at least a basic understanding of immunosuppression and its complications.
Padiyar
Aparna
A
Division of Nephrology, Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA.
Akoum
Fadi H
FH
Hricik
Donald E
DE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001847:Bone Diseases / Q000209:etiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003141:Communicable Diseases / Q000209:etiology; D003920:Diabetes Mellitus / Q000209:etiology / Q000517:prevention & control; D006084:Graft Rejection / Q000188:drug therapy* / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects*; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control; D017063:Outcome Assessment, Health Care; D016032:Randomized Controlled Trials as Topic; D014481:United States
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents